All In Biotech

Drug Trial Radar · NCT03974022

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR or HER2 Mutation

Last checked: Nov 20, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

315

Actual

Start

Jul 9, 2019

Primary completion

Jul 29, 2024

Study completion Dec 2026

Sponsor

Lead sponsor
Dizal PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jun 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have progressed following prior therapy. This is the first time this drug is tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • SunvozertinibDrug

    Daily dose of Sunvozertinib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A Dose Escalation: Dose Limiting Toxicities (DLTs).Time frame: The DLT observation period is defined as the 28 days after the first multiple dose (up to 36 days from baseline).
  2. Part B: Objective Response Rate (ORR) According to RECIST 1.1 by an Independent Review Committee (IRC).Time frame: through the study completion, an average of around 1 year for part B

Locations

124 sites in 13 countries. Site status is shown where the registry gives one.

  • University of California, San Diego (UCSD) - Moores Cancer Center

    La Jolla, California

  • University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center

    Orange, California

  • Innovative Clinical Research Institute, LLC

    Whittier, California

  • University of Colorado Hospital - Anschutz Cancer Pavilion

    Aurora, Colorado

  • H. Lee Moffitt Cancer Center & Research Institute

    Tampa, Florida

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Michigan Center of Medical Research

    Farmington Hills, Michigan

  • Northwell Health - Centers for Advanced Medicine

    New Hyde Park, New York

  • Laura and Isaac Perlmutter Cancer Center

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Fundacion Respirar - Consultorios Medicos Dr. Doreski

    Cabildo, Argentina

  • CEMIC Centro de Educación Médica e Investigaciones Clínicas - Hospital Universitario sede Saavedra

    Ciudad Autónoma Buenos Aires, Argentina

  • Centro Medico Austral OMI

    Ciudad Autónoma Buenos Aires, Argentina

  • Diabaid

    Ciudad Autónoma Buenos Aires, Argentina

  • Fundacion CENIT Para La Investigacion en Neurociencias

    Ciudad Autónoma Buenos Aires, Argentina

  • Instituto Argentino de Diagnositco y Tratamiento S.A.

    Ciudad Autónoma Buenos Aires, Argentina

  • Instituto Medico de la Fundacion de Estudios Clínicos

    Ciudad Autónoma Buenos Aires, Argentina

  • Centro de Investigación Pergamino SA

    Pergamino, Argentina

  • Clinica Viedma S.A

    Viedma, Argentina

  • Blacktown Hospital

    Blacktown, Australia

  • Chris O'Brien Lifehouse

    Camperdown, Australia

  • Austin Hospital

    Heidelberg, Australia

  • St George Hospital

    Kogarah, Australia

  • Peter MacCallum Cancer Centre - East Melbourne

    North Melbourne, Australia

  • Linear Cancer trials

    Perth, Australia

  • Southern Medical Day Care Centre

    Wollongong, Australia

  • Princess Margaret Cancer Centre

    Toronto, Canada

  • Fundación Arturo López Pérez

    Providencia, Chile

  • Orlandi Oncología - Centro Médico Health & Care

    Santiago, Chile

  • SAGA

    Santiago, Chile

  • James Lind Centro De Investigacion Del Cancer

    Temuco, Chile

  • Beijing Cancer Hospital

    Beijing, China

  • Beijing Chest Hospital,Capital Medical University

    Beijing, China

  • Peking Union Medical College Hospital

    Beijing, China

  • Jilin Cancer Hospital

    Changchun, China

  • Hunan Cancer Hospital

    Changsha, China

  • West China Hospital of Sichuan University

    Chengdu, China

  • Chongqing Cancer Hospital

    Chongqing, China

Showing 40 of 124 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.